How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?

Several randomized controlled trials of anti-estrogens, such as tamoxifen and aromatase inhibitors, have demonstrated up to a 50–65% decrease in breast cancerincidence among high-risk women. Approximately 15% of women, age 35–79 years, in the U.S. meet criteria for breast cancer preventive therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Crew, Katherine D., Albain, Kathy S., Hershman, Dawn L., Unger, Joseph M., Lo, Shelly S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460136/
https://www.ncbi.nlm.nih.gov/pubmed/28649660
http://dx.doi.org/10.1038/s41523-017-0021-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460136/
https://www.ncbi.nlm.nih.gov/pubmed/28649660
http://dx.doi.org/10.1038/s41523-017-0021-y

Ejemplares similares